Dr. Reddy's Laboratories Announces the Launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. Market
July 11 2018 - 2:51AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) today announced the launch of Hydroxychloroquine Sulfate
Tablets USP, 200 mg, a therapeutic equivalent generic version of
Plaquenil® (hydroxychloroquine sulfate) Tablets, in the U.S.
market, approved by the U.S. Food and Drug Administration
(USFDA).
The Plaquenil® brand and generic had U.S. sales of approximately
$215 million MAT for the most recent twelve months ending in May
2018 according to IMS Health*.
Dr. Reddy’s Hydroxychloroquine Sulfate Tablets are available in
200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil® is a trademark of Concordia International Corp.
*IMS National Sales Perspective: Retail and Non-Retail MAT May
2018RDY-0618-209
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180710006116/en/
Dr. Reddy’s Laboratories Ltd.INVESTOR
RELATIONSSAUNAK SAVLA,
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN
PRINTER, +91-40-49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024